Skip to main content
Alnylam Pharmaceuticals, Inc. (LON:0HD2)
London flag London · Delayed Price · Currency is GBP · Price in USD
262.11
+2.19 (0.84%)
At close: May 12, 2025

Alnylam Pharmaceuticals Revenue

Alnylam Pharmaceuticals had revenue of $594.19M USD in the quarter ending March 31, 2025, with 20.20% growth. This brings the company's revenue in the last twelve months to $2.35B, up 17.21% year-over-year. In the year 2024, Alnylam Pharmaceuticals had annual revenue of $2.25B with 22.97% growth.

Revenue (ttm)
$2.35B
Revenue Growth
+17.21%
P/S Ratio
14.67
Revenue / Employee
$1.05M
Employees
2,230
Market Cap
26.67B GBP

Revenue Chart

* This company reports financials in USD.

History

Fiscal Year End Revenue Change Growth
Dec 31, 20242.25B419.95M22.97%
Dec 31, 20231.83B790.87M76.23%
Dec 31, 20221.04B193.13M22.88%
Dec 31, 2021844.29M351.43M71.31%
Dec 31, 2020492.85M273.10M124.28%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
AstraZeneca 42.56B
GSK plc 31.53B
Haleon 11.23B
Smith & Nephew 4.64B
ConvaTec Group 1.83B
Hikma Pharmaceuticals 2.50B
HUTCHMED (China) 503.39M
Genus 671.60M
Revenue Rankings

Alnylam Pharmaceuticals News

More News